PMID- 36198685
OWN - NLM
STAT- MEDLINE
DCOM- 20221007
LR  - 20221024
IS  - 2059-3635 (Electronic)
IS  - 2095-9907 (Print)
IS  - 2059-3635 (Linking)
VI  - 7
IP  - 1
DP  - 2022 Oct 5
TI  - Signaling pathways and targeted therapies in lung squamous cell carcinoma: 
      mechanisms and clinical trials.
PG  - 353
LID - 10.1038/s41392-022-01200-x [doi]
LID - 353
AB  - Lung cancer is the leading cause of cancer-related death across the world. Unlike 
      lung adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not 
      benefitted from targeted therapies. Although immunotherapy has significantly 
      improved cancer patients' outcomes, the relatively low response rate and severe 
      adverse events hinder the clinical application of this promising treatment in 
      LSCC. Therefore, it is of vital importance to have a better understanding of the 
      mechanisms underlying the pathogenesis of LSCC as well as the inner connection 
      among different signaling pathways, which will surely provide opportunities for 
      more effective therapeutic interventions for LSCC. In this review, new insights 
      were given about classical signaling pathways which have been proved in other 
      cancer types but not in LSCC, including PI3K signaling pathway, VEGF/VEGFR 
      signaling, and CDK4/6 pathway. Other signaling pathways which may have 
      therapeutic potentials in LSCC were also discussed, including the FGFR1 pathway, 
      EGFR pathway, and KEAP1/NRF2 pathway. Next, chromosome 3q, which harbors two key 
      squamous differentiation markers SOX2 and TP63 is discussed as well as its 
      related potential therapeutic targets. We also provided some progress of LSCC in 
      epigenetic therapies and immune checkpoints blockade (ICB) therapies. 
      Subsequently, we outlined some combination strategies of ICB therapies and other 
      targeted therapies. Finally, prospects and challenges were given related to the 
      exploration and application of novel therapeutic strategies for LSCC.
CI  - (c) 2022. The Author(s).
FAU - Niu, Zhenyi
AU  - Niu Z
AD  - Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University 
      School of Medicine, 197 Ruijin 2nd Road, Shanghai, China.
FAU - Jin, Runsen
AU  - Jin R
AD  - Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University 
      School of Medicine, 197 Ruijin 2nd Road, Shanghai, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Immunology and Microbiology, Shanghai Jiao Tong University School 
      of Medicine, 280 South Chongqing Road, Shanghai, China. zhy3331a@shsmu.edu.cn.
FAU - Li, Hecheng
AU  - Li H
AD  - Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University 
      School of Medicine, 197 Ruijin 2nd Road, Shanghai, China. 
      lihecheng2000@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221005
PL  - England
TA  - Signal Transduct Target Ther
JT  - Signal transduction and targeted therapy
JID - 101676423
RN  - 0 (Kelch-Like ECH-Associated Protein 1)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Carcinoma, Squamous Cell/drug therapy/genetics/metabolism
MH  - ErbB Receptors/metabolism
MH  - Humans
MH  - Kelch-Like ECH-Associated Protein 1/metabolism
MH  - Lung/pathology
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - NF-E2-Related Factor 2/metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Signal Transduction/genetics
MH  - Vascular Endothelial Growth Factor A
PMC - PMC9535022
COIS- The authors declare no competing interests.
EDAT- 2022/10/06 06:00
MHDA- 2022/10/12 06:00
PMCR- 2022/10/05
CRDT- 2022/10/05 23:16
PHST- 2022/06/01 00:00 [received]
PHST- 2022/09/18 00:00 [accepted]
PHST- 2022/09/03 00:00 [revised]
PHST- 2022/10/05 23:16 [entrez]
PHST- 2022/10/06 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/10/05 00:00 [pmc-release]
AID - 10.1038/s41392-022-01200-x [pii]
AID - 1200 [pii]
AID - 10.1038/s41392-022-01200-x [doi]
PST - epublish
SO  - Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 
      10.1038/s41392-022-01200-x.